Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $4 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $4 price target.
Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $4 price target.